Lee et al., 2024 - Google Patents
Akt1 is involved in HCV release by promoting endoplasmic reticulum-to-endosome transition of infectious virionsLee et al., 2024
- Document ID
- 4211324660259594
- Author
- Lee W
- Liao S
- Huang Y
- Hou M
- Lan K
- Publication year
- Publication venue
- Life Sciences
External Links
Snippet
Abstract Aims Hepatitis C virus (HCV) relies on the viral and host factors to complete its life cycle. It has evolved to profit from Akt activation at some stage in its life cycle through various mechanisms, notably by activating lipogenesis, which is crucial for infectious virions …
- 101150045355 akt1 gene 0 title abstract description 119
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity | |
| Park et al. | Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway | |
| Cao et al. | MDA5 plays a critical role in interferon response during hepatitis C virus infection | |
| Saeed et al. | SEC14L2 enables pan-genotype HCV replication in cell culture | |
| Wang et al. | Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response | |
| Xu et al. | MiR-221 accentuates IFN׳ s anti-HCV effect by downregulating SOCS1 and SOCS3 | |
| Chusri et al. | HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response | |
| EP2399988A2 (en) | Cell culture system for replication of HCV through the farnesoid X receptor (FXR) activation or inhibition and diagnostic method for HCV infection | |
| Fusco et al. | A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication | |
| Dansako et al. | Rab18 is required for viral assembly of hepatitis C virus through trafficking of the core protein to lipid droplets | |
| Scholtes et al. | Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR | |
| Kobayashi et al. | Rab8b regulates transport of West Nile virus particles from recycling endosomes | |
| Kim et al. | Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma | |
| Kong et al. | Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response | |
| Ren et al. | Identification of syntaxin 4 as an essential factor for the hepatitis C virus life cycle | |
| Liu et al. | Exosome-transmitted circ-CARD6 facilitates posterior capsule opacification development by miR-31/FGF7 axis | |
| Vallianou et al. | Hepatitis C virus suppresses hepatocyte nuclear factor 4 alpha, a key regulator of hepatocellular carcinoma | |
| Boyer et al. | TM6SF2 promotes lipidation and secretion of hepatitis C virus in infected hepatocytes | |
| Qin et al. | Fetal bovine serum inhibits hepatitis C virus attachment to host cells | |
| Lee et al. | Akt1 is involved in HCV release by promoting endoplasmic reticulum-to-endosome transition of infectious virions | |
| TWI616528B (en) | Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof | |
| Zhang et al. | The nuclear protein Sam68 is recruited to the cytoplasmic stress granules during enterovirus 71 infection | |
| US20090186039A1 (en) | Novel use of grp 94 in virus infection | |
| Li et al. | AP1S3 is required for hepatitis C virus infection by stabilizing E2 protein | |
| Lee et al. | Akt1 is required to maintain lipid droplets for release of HCV infectious virions |